 This issue of JCP Visuals is available in Adobe Acrobat Portable Document Format (PDF). For a description of PDF and Adobe Acrobat Reader, please visit our Online Media Page. Download the Posttest (if you prefer not to take the Posttest online for instant credit) |
To obtain credit, please
study the activity material and complete the posttest as
instructed. CME Objectives After completing this educational activity, participants should be able to:
Statement of Need and Purpose Attention-deficit/hyperactivity
disorder (ADHD) has been reported to affect 2% to 6% of
adults. Stimulants are effective in treating ADHD but
require several doses. In recent years, a nonstimulant
medication as well as long-acting formulations of the
older stimulants received approval for ADHD. Physicians
need education about the properties of the new
medications, as well as about diagnosis, in order to
effectively treat patients. This activity was designed to
meet the needs of participants in CME activities provided
by Physicians Postgraduate Press, Inc. who Accreditation Statement Physicians Postgraduate Press, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Physicians Postgraduate Press, Inc. designates this educational activity for up to 1 Category 1 credit toward the AMA Physician's Recognition Award. Each participant should claim only those credits that he/she actually spent in the educational activity. Date of Original Release/Review This JCP Visuals was published in June 2004 and is eligible for CME credit through June 30, 2006. The latest review of this material was May 2004. Faculty David A. Baron, M.S.Ed.,
D.O. Matthew A. Menza, M.D.
Michael G. Wise, M.D.
Faculty Disclosure In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this continuing medical education activity were asked to complete a full disclosure statement. The information received is as follows: Dr. Baron is a consultant for AstraZeneca and Eli Lilly; has received grant/research support from Pfizer, Eli Lilly, Janssen, and Johnson & Johnson; has received honoraria from Janssen, Eli Lilly, and AstraZeneca; and is a member of the speakers/advisory boards of Janssen, Pfizer, Eli Lilly, and AstraZeneca. Dr. Menza has received grant/research support from National Institutes of Health, Pfizer, Merck, AstraZeneca, Wyeth, Cephalon, Eli Lilly, GlaxoSmithKline, Bristol-Myers Squibb, Forest, Pharmacia, Novartis, Hoechst Marion Roussel, and Bayer; has received honoraria from Pfizer, AstraZeneca, Wyeth, Cephalon, Eli Lilly, Bristol-Myers Squibb, and Pharmacia; and is a consultant for Pfizer, Cephalon, Eli Lilly, GlaxoSmithKline, Bristol-Myers Squibb, Forest, Hoechst Marion Roussel, and Bayer. Dr. Wise is a consultant for Eli Lilly, Bristol-Myers Squibb, Pfizer, and Ortho-McNeil; and is a member of the speakers/advisory boards of Eli Lilly, Bristol-Myers Squibb, and Pfizer. Disclosure of Off-Label Usage The chair has determined that, to the best of his knowledge, bupropion, desipramine, and venlafaxine are not approved by the U.S. Food and Drug Administration for the treatment of attention-deficit/hyperactivity disorder. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Acknowledgment This JCP Visuals was derived from the teleconference “Recent Advances in Adult ADHD Care,” which was held February 9, 2004, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc. pursuant to an unrestricted educational grant from Eli Lilly and Company. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the CME provider and publisher or the commercial supporter. |